These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23101460)

  • 1. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study.
    Heijnen IA; Foocharoen C; Bannert B; Carreira PE; Caporali R; Smith V; Kumánovics G; Becker MO; Vanthuyne M; Simsek I; Bocelli-Tyndall C; Walker UA
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):96-102. PubMed ID: 23101460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.
    Dick T; Mierau R; Bartz-Bazzanella P; Alavi M; Stoyanova-Scholz M; Kindler J; Genth E
    Ann Rheum Dis; 2002 Feb; 61(2):121-7. PubMed ID: 11796397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.
    Foocharoen C; Suwannachat P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R;
    Int J Rheum Dis; 2016 Mar; 19(3):312-20. PubMed ID: 25293362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais.
    Foocharoen C; Watcharenwong P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R
    Int J Rheum Dis; 2017 Oct; 20(10):1572-1581. PubMed ID: 28296274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bibliographical study of the concurrent existence of anticentromere and antitopoisomerase I antibodies.
    Kikuchi M; Inagaki T
    Clin Rheumatol; 2000; 19(6):435-41. PubMed ID: 11147751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.
    Walker UA; Tyndall A; Czirják L; Denton C; Farge-Bancel D; Kowal-Bielecka O; Müller-Ladner U; Bocelli-Tyndall C; Matucci-Cerinic M
    Ann Rheum Dis; 2007 Jun; 66(6):754-63. PubMed ID: 17234652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of systemic sclerosis with anticentromere, antitopoisomerase I, and anti-U1RNP antibodies.
    Sato S; Ihn H; Soma Y; Shimozuma M; Shishiba T; Takehara K
    J Rheumatol; 1993 Nov; 20(11):1961-3. PubMed ID: 8308786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis.
    Iniesta Arandia N; Simeón-Aznar CP; Guillén Del Castillo A; Colunga Argüelles D; Rubio-Rivas M; Trapiella Martínez L; García Hernández FJ; Sáez Comet L; Egurbide Arberas MV; Ortego-Centeno N; Freire M; Marí Alfonso B; Vargas Hitos JA; Ríos Blanco JJ; Todolí Parra JA; Rodríguez-Carballeira M; Marín Ballvé A; Chamorro Fernández AJ; Pla Salas X; Madroñero Vuelta AB; Ruiz Muñoz M; Fonollosa Pla V; Espinosa G;
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):98-105. PubMed ID: 28980912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study.
    Rozman B; Cucnik S; Sodin-Semrl S; Czirják L; Varjú C; Distler O; Huscher D; Aringer M; Steiner G; Matucci-Cerinic M; Guiducci S; Stamenkovic B; Stankovic A; Kveder T
    Ann Rheum Dis; 2008 Sep; 67(9):1282-6. PubMed ID: 18063672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and serological heterogeneity in patients with anticentromere antibodies.
    Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
    J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts.
    Liem SIE; Boonstra M; le Cessie S; Riccardi A; Airo P; Distler O; Matucci-Cerinic M; Caimmi C; Siegert E; Allanore Y; Huizinga TWJ; Toes REM; Scherer HU; de Vries-Bouwstra JK;
    Lancet Rheumatol; 2022 Oct; 4(10):e699-e709. PubMed ID: 38265968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and immunological differences between Japanese patients with diffuse scleroderma and limited scleroderma.
    Satoh M; Akizuki M; Kuwana M; Mimori T; Yamagata H; Yoshida S; Homma M; Yamamoto T; Sasazuki T
    J Rheumatol; 1994 Jan; 21(1):111-4. PubMed ID: 8151564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic sclerosis in Argentina: evaluation of a large cohort from a single centre and comparison with other international series.
    Scolnik M; Lancioni E; Saucedo C; Marin J; Sabelli M; Bedran Z; Soriano ER; Catoggio LJ
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-94-7. PubMed ID: 25198424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
    Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
    Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Could the IgA isotype provide additional information in systemic sclerosis patients? A retrospective study entailing IgA isotyping in a Mediterranean systemic sclerosis cohort.
    Pérez-Isidro A; Lledó-Ibáñez GM; de Moner N; Torradeflot M; Martínez MJ; Espinosa G; Tena Campos M; Grundhuber M; Viñas O; Ruiz-Ortiz E
    Clin Exp Rheumatol; 2024 Aug; 42(8):1556-1563. PubMed ID: 37812465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoblotting on HEp-2 cells increases the detection of antitopoisomerase 1 antibodies in patients with systemic sclerosis.
    Tamby MC; Servettaz A; Guilpain P; Tamas N; Berezné A; Batteux F; Reinbolt J; Guillevin L; Weill B; Mouthon L
    Clin Immunol; 2007 Apr; 123(1):82-8. PubMed ID: 17258939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-sectional study using the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0 (UCLA SCTC GIT 2.0) for gastrointestinal disorders of systemic sclerosis.
    Hisada S; Takeuchi S; Tozawa T; Yamada Y; Ito Y; Kodera M
    J Dermatol; 2024 Oct; 51(10):1329-1334. PubMed ID: 38963343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis.
    Sobanski V; Giovannelli J; Allanore Y; Riemekasten G; Airò P; Vettori S; Cozzi F; Distler O; Matucci-Cerinic M; Denton C; Launay D; Hachulla E;
    Arthritis Rheumatol; 2019 Sep; 71(9):1553-1570. PubMed ID: 30969034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and clinical profiles of 'autoantibody-negative' systemic sclerosis subjects.
    Hudson M; Satoh M; Chan JY; Tatibouet S; Mehra S; Baron M; Fritzler M;
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-127-32. PubMed ID: 24144389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement.
    Mitri GM; Lucas M; Fertig N; Steen VD; Medsger TA
    Arthritis Rheum; 2003 Jan; 48(1):203-9. PubMed ID: 12528120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.